Charles Schwab Investment Management Inc. Boosts Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Charles Schwab Investment Management Inc. raised its holdings in Eli Lilly and Company (NYSE:LLY) by 4.1% in the 4th quarter, Holdings Channel.com reports. The firm owned 5,035,084 shares of the company’s stock after acquiring an additional 199,864 shares during the period. Eli Lilly and Company makes up 0.7% of Charles Schwab Investment Management Inc.’s investment portfolio, making the stock its 25th largest position. Charles Schwab Investment Management Inc.’s holdings in Eli Lilly and Company were worth $3,887,085,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the business. WMG Financial Advisors LLC increased its stake in shares of Eli Lilly and Company by 98.3% in the fourth quarter. WMG Financial Advisors LLC now owns 950 shares of the company’s stock worth $733,000 after purchasing an additional 471 shares in the last quarter. Steward Partners Investment Advisory LLC increased its stake in shares of Eli Lilly and Company by 13.5% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 72,222 shares of the company’s stock worth $55,756,000 after purchasing an additional 8,591 shares in the last quarter. Schechter Investment Advisors LLC boosted its position in shares of Eli Lilly and Company by 8.9% in the fourth quarter. Schechter Investment Advisors LLC now owns 7,723 shares of the company’s stock valued at $5,962,000 after acquiring an additional 630 shares during the period. Bravias Capital Group LLC bought a new position in shares of Eli Lilly and Company in the fourth quarter valued at approximately $203,000. Finally, Wernau Asset Management Inc. bought a new position in shares of Eli Lilly and Company in the fourth quarter valued at approximately $329,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 1.0 %

LLY stock opened at $930.22 on Tuesday. The company has a market capitalization of $882.01 billion, a PE ratio of 79.44, a price-to-earnings-growth ratio of 1.40 and a beta of 0.42. Eli Lilly and Company has a one year low of $711.40 and a one year high of $972.53. The company’s 50 day moving average price is $817.56 and its two-hundred day moving average price is $848.11. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. As a group, analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company declared that its Board of Directors has approved a stock repurchase program on Monday, December 9th that permits the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization permits the company to repurchase up to 2% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s leadership believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be paid a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.65%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date is Friday, February 14th. Eli Lilly and Company’s payout ratio is presently 51.24%.

Analyst Ratings Changes

A number of research firms have recently commented on LLY. Redburn Atlantic upgraded shares of Eli Lilly and Company to a “hold” rating in a research report on Monday, November 4th. Leerink Partners set a $950.00 price objective on shares of Eli Lilly and Company in a research report on Friday, January 17th. Wells Fargo & Company cut their price objective on shares of Eli Lilly and Company from $1,000.00 to $970.00 and set an “overweight” rating for the company in a research report on Tuesday, January 28th. Citigroup cut their price objective on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research report on Tuesday, January 28th. Finally, Truist Financial raised their price objective on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a research report on Monday, February 3rd. Three analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,000.28.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.